000309828 001__ 309828
000309828 005__ 20260212161416.0
000309828 0247_ $$2doi$$a10.1093/neuonc/noag024
000309828 0247_ $$2pmid$$apmid:41671098
000309828 0247_ $$2ISSN$$a1522-8517
000309828 0247_ $$2ISSN$$a1523-5866
000309828 037__ $$aDKFZ-2026-00333
000309828 041__ $$aEnglish
000309828 082__ $$a610
000309828 1001_ $$0P:(DE-He78)b769be55bb53da2335ffbfdab5ddb1b6$$aIppen, Franziska$$b0$$eFirst author
000309828 245__ $$aThe prognostic impact of CDKN2A/B hemizygous deletions in meningioma.
000309828 260__ $$aOxford$$bOxford Univ. Press$$c2026
000309828 3367_ $$2DRIVER$$aarticle
000309828 3367_ $$2DataCite$$aOutput Types/Journal article
000309828 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1770909228_1406597
000309828 3367_ $$2BibTeX$$aARTICLE
000309828 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000309828 3367_ $$00$$2EndNote$$aJournal Article
000309828 500__ $$a#EA:B300#LA:B300# / #DKTKZFB26# / #NCTZFB26# / epub
000309828 520__ $$aMeningiomas are the most common adult brain tumors. While homozygous deletions of CDKN2A/B are linked to early recurrence and hence serve as CNS WHO grade 3 criterion, the clinical impact of hemizygous deletions remains unclear-especially since distinguishing between hemi- and homozygous losses can be technically challenging.DNA methylation data, copy-number and mutation data were evaluated on a multicenter cohort of 970 meningiomas. Each sample's CDKN2A/B status was manually classified by visual inspection in relation to whole chromosomal losses and gains in the copy number profile generated from global methylation array in relation to other copy number events. Progression probabilities were determined using the Kaplan-Meier method.Among 970 meningiomas, n = 30 had homozygous, n = 114 hemizygous (n = 31 segmental; n = 83 focal) and n = 826 CDKN2A/B balanced status. In cases with hemizygous deletions in general, an association with increased progression risk compared to balanced cases was observed, although this did not reach statistical significance (log-rank p = 0.074; HR 1.36, 95% CI [0.97, 1.90]; p = 0.07). However, segmental hemizygous losses were linked to a significantly worse prognosis (log-rank p = 0.0023), but focal hemizygous deletions were not (log-rank p = 0.523). Segmental hemizygous CDKN2A/B deletions were more frequently associated with a higher amount of high-risk copy number variations (CNVs) than focal losses.Our findings suggest that hemizygous CDKN2A/B deletions overall do not confer worse risks for progression in meningiomas. The signal for segmental deletions may not be locus-specific but just one representation of the generally instable genome of aggressive meningiomas.
000309828 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000309828 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000309828 650_7 $$2Other$$aCDKN2A/B
000309828 650_7 $$2Other$$ahemizygous deletion
000309828 650_7 $$2Other$$ameningioma
000309828 650_7 $$2Other$$aprogression-free survival
000309828 7001_ $$0P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aHielscher, Thomas$$b1$$udkfz
000309828 7001_ $$0P:(DE-He78)79506056c05e539af84edf040f0a93ad$$aPatel, Areeba Jamilkhan$$b2$$udkfz
000309828 7001_ $$0P:(DE-He78)263d95a5b6ba4abce7abee7185b9630e$$aFriedel, Dennis$$b3$$udkfz
000309828 7001_ $$0P:(DE-He78)91f2043e3a8b3c5d31ec010fc634b118$$aGöbel, Kirsten$$b4
000309828 7001_ $$0P:(DE-He78)8aad075b17d93a5636a34942bdbd7ee6$$aSievers, Philipp$$b5$$udkfz
000309828 7001_ $$aAcker, Till$$b6
000309828 7001_ $$aSnuderl, Matija$$b7
000309828 7001_ $$aBrandner, Sebastian$$b8
000309828 7001_ $$aWeller, Michael$$b9
000309828 7001_ $$aPreusser, Matthias$$b10
000309828 7001_ $$aMaas, Sybren L N$$b11
000309828 7001_ $$0P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$avon Deimling, Andreas$$b12$$udkfz
000309828 7001_ $$0P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aWick, Wolfgang$$b13$$udkfz
000309828 7001_ $$aBi, Wenya Linda$$b14
000309828 7001_ $$0P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88$$aSahm, Felix$$b15$$eLast author$$udkfz
000309828 7001_ $$0P:(DE-He78)c77fccff3e6c42b017b2e8a09813590c$$aSuwala, Abigail Kora$$b16$$eLast author$$udkfz
000309828 773__ $$0PERI:(DE-600)2094060-9$$a10.1093/neuonc/noag024$$gp. noag024$$pnn$$tNeuro-Oncology$$vnn$$x1522-8517$$y2026
000309828 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b769be55bb53da2335ffbfdab5ddb1b6$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000309828 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000309828 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)79506056c05e539af84edf040f0a93ad$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000309828 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)263d95a5b6ba4abce7abee7185b9630e$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000309828 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)91f2043e3a8b3c5d31ec010fc634b118$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000309828 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8aad075b17d93a5636a34942bdbd7ee6$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000309828 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000309828 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000309828 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000309828 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c77fccff3e6c42b017b2e8a09813590c$$aDeutsches Krebsforschungszentrum$$b16$$kDKFZ
000309828 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000309828 9141_ $$y2026
000309828 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-11$$wger
000309828 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEURO-ONCOLOGY : 2022$$d2024-12-11
000309828 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-11
000309828 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-11
000309828 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-11
000309828 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-11
000309828 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-11
000309828 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-11
000309828 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-11
000309828 915__ $$0StatID:(DE-HGF)9915$$2StatID$$aIF >= 15$$bNEURO-ONCOLOGY : 2022$$d2024-12-11
000309828 9202_ $$0I:(DE-He78)B300-20160331$$kB300$$lKKE Neuropathologie$$x0
000309828 9201_ $$0I:(DE-He78)B300-20160331$$kB300$$lKKE Neuropathologie$$x0
000309828 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000309828 9201_ $$0I:(DE-He78)HD02-20160331$$kHD02$$lKoordinierungsstelle NCT Heidelberg$$x2
000309828 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x3
000309828 9201_ $$0I:(DE-He78)B320-20160331$$kB320$$lKKE Neuroonkologie$$x4
000309828 9200_ $$0I:(DE-He78)B300-20160331$$kB300$$lKKE Neuropathologie$$x0
000309828 980__ $$ajournal
000309828 980__ $$aVDB
000309828 980__ $$aI:(DE-He78)B300-20160331
000309828 980__ $$aI:(DE-He78)HD01-20160331
000309828 980__ $$aI:(DE-He78)HD02-20160331
000309828 980__ $$aI:(DE-He78)C060-20160331
000309828 980__ $$aI:(DE-He78)B320-20160331
000309828 980__ $$aUNRESTRICTED